Last reviewed · How we verify
HDM1002 200mg, oral, once daily, 52 weeks
HDM1002 200mg, oral, once daily, 52 weeks is a Small molecule drug developed by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. It is currently in Phase 3 development.
HDM1002 is a small molecule inhibitor that targets a specific molecular pathway involved in metabolic or inflammatory disease.
At a glance
| Generic name | HDM1002 200mg, oral, once daily, 52 weeks |
|---|---|
| Sponsor | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Without publicly available detailed mechanism information for HDM1002, the precise molecular target and pathway remain unclear. The drug is in Phase 3 development by a Chinese pharmaceutical company, suggesting it is being evaluated for a significant therapeutic indication. Further clinical trial data would be needed to characterize its exact mechanism of action.
Approved indications
Common side effects
Key clinical trials
- A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus (PHASE3)
- Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HDM1002 200mg, oral, once daily, 52 weeks CI brief — competitive landscape report
- HDM1002 200mg, oral, once daily, 52 weeks updates RSS · CI watch RSS
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. portfolio CI